Kairos Pharma Reports Interim PFS Benefit For ENV-105 In Phase 2 Prostate Cancer Trial
Kairos Pharma (KAPA) reported positive interim data from its Phase 2 trial of ENV-105 combined with apalutamide for metastatic prostate cancer. The combination showed a median progression-free survival of 17.7 months vs. 2 months with apalutamide alone. The company modified the trial protocol to enroll patients earlier. KAPA's stock is down 0.65% at $1.54.
How this was made
The 30-second read
Why it matters
The statistically significant PFS improvement may drive near‑term buying interest and raise the company's valuation.
Market read
New trial data provides a fresh catalyst for KAPA, potentially influencing biotech sector sentiment.
What to watch
Future regulatory review and larger Phase 3 data remain uncertain.
Background
Kairos Pharma announced interim efficacy data from its Phase 2 trial of ENV-105 in metastatic castration‑resistant prostate cancer.
Ticker impact
Interim Phase 2 data shows ENV-105 plus apalutamide improves median PFS to 17.7 months versus 2 months alone.
likely upward pressure as investors price in the efficacy signal
Statistically significant PFS improvement and protocol expansion suggest stronger market potential.
Market effects
May lift sentiment in the broader biotech/oncology sector.
US biotech investors could see increased interest.
Limited to biotech investors; no broad market effect.
Counterpoint
If the data does not translate to overall survival benefit, the rally could be short-lived.
Key entities
- companyKairos Pharma Ltd.
Clinical‑stage biopharma developing ENV-105.
- drugENV-105
Antibody targeting CD105 in prostate cancer.
